Bank of Israel suspends choice of Hapoalim CEO

Bank of Israel Supervisor of Banks Rony Hizkiyahu ordered an investigation into the Hapoalim appointment.

March 30, 2009 09:24
bank poalim 88 298

A Bank Hapoalim branch 248.88. (photo credit: Ariel Jerozolimski)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Bank of Israel Supervisor of Banks Rony Hizkiyahu on Sunday ordered Bank Hapoalim to hold up approval of its new chief executive officer, Zion Keinan, until an investigation into the appointment is completed. Bank Hapoalim announced the appointment of Keinan, a 30-year Hapoalim veteran, as the replacement for Zvi Ziv, who resigned as last week. The central bank has launched an investigation into the reasons for Ziv's resignation and the proper procedure for Keinan's appointment. Hapoalim said Keinan's decades of experience at the bank turned him into the natural replacement for Ziv. Keinan served as Ziv's deputy and head of corporate banking.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection